

# Regimen for Thoracic Oncology (2024)

## Table of contents
### NSCLC
- Neoadjuvant
- Nivolumab + AP (Pemetrexed/Cisplatin)
- Nivolumab + AP (Pemetrexed/Cisplatin)
- Nivolumab + GP (Gemcitabine/Cisplatin)
- Nivolumab + TC (Paclitaxel/Carboplatin)
- GP (Neoadjuvant)
- Pembrolizumab + AP (Pemetrexed/Cisplatin)
- Pembrolizumab + GP (Gemcitabine/Cisplatin)
- Durvalumab + AP (Pemetrexed/Cisplatin)
- Durvalumab + GP (Gemcitabine/Cisplatin)

### Adjuvant
- NP (Vinorelbine/Cisplatin)
- AP (Pemetrexed/Cisplatin)
- AC (Pemetrexed/Carboplatin)
- TC (Paclitaxel/Carboplatin)
- Atezolizumab (허가만족, PD-L1(SP263)≥50%)
- Pembrolizumab (허가만족, PD-L1 all comer)

### CCRT & Consolidation
- CCRT with weekly TC
- Durvalumab (Consolidation)


### Palliative
- Pembrolizumab+Pemetrexed+Carboplatin (1st line)
- Pembrolizumab+Pemetrexed+Cisplatin (1st line)
- Pembrolizumab+Paclitaxel+Carboplatin (1st line)
<!-- -->
- Pembrolizumab (1st line)
- Pembrolizumab (≥2nd line)
- Nivolumab (≥2nd line, q 2 weeks)
- Atezolizumab (≥2nd line)
<!-- -->
- Amivantamab (허가만족)
<!-- -->
- Trastuzumab Deruxtecan (허가만족)
<!-- -->
- Pemetrexed (≥2nd line)
- Pemetrexed (Maintenance)
- Pemetrexed/Cisplatin
- Pemetrexed/Carboplatin
<!-- -->
- Docetaxel
- Weekly docetaxel
- DP
- Weekly DP
- DC
- Weekly DC
<!-- -->
- Paclitaxel      
- Weekly Paclitaxel       
- TP              
- Weekly TP
- TC              
- Weekly TC 
- TC+Avastin
 <!-- -->
- Gemcitabine    
- GP (Palliative)
- GP+Avastin     
- GC             
- GN
<!-- -->
- Vinorelbine (3-Weekly)
- Vinorelbine+Carboplatin        
- NP       
- VI
<!-- -->
- EP          
- EC               
- Irinotecan
<!-- -->
- (Sarcomatoid)                  
- IA (IIT trial)         
- VIP
<!-- -->

---

### Neoadjuvant Nivolumab plus Pemetrexed/Cisplatin for NSCLC (nonsquamous) (허가만족 100/100)

BSA:    m2

Nivolumab [D-code]    360 mg (fixed) miv over 30 min (with filter)
NS 50 mL
D1

Pemetrexed [D-code]     mg (500 mg/m2) miv over 10 minutes
N/S 50 mL 
(Pemed S로 처방할 경우 N/S 100 mL)
(total dose 625 mg 미만일 경우 NS 60 mL mix)
D1

Cisplatin [D-code]         mg (75 mg/m2) miv over 15 min.
N/S 150 mL 
D1 

q 3 weeks (for 3 cycles)

>▶투약순서: Nivolumab → Prehydration (2 hr) → Alimta → dexa, Antiemetics (-30 min) → 15% mannitol (-15 min) → CDDP → Posthydration (2 hr) [# Prehydration 시작 후 1시간 20분 후 Alimta 시작]

##### Supportive cares
1. Antiemetics(고위험군) (보험):
D1 Akynzeo (Netupitant + palonosetron) PO; dexa는 pemetrexed premed로 대체
2. To reduce toxicities
- Actinamide 1 mg IM: 1 week before 1st dose, q 9 weeks
  (1 wk before 1st cycle, 4th,7th,10th…. cycle after then.)
- Folic acid 1 mg daily: 1 week before 1st dose until 3 weeks after last dose
3. To minimize cutaneous reactions: Dexa 4 mg po bid on D0-2 (1st cycle에 dexamethasone premedication 하지 못한 경우에만 iv dexamethasone 12 mg 처방합니다.)
4. Hydration
- ONH with Oral hydration 1.5 L 
- CDDP: pre/post NK2 2L, 15% mannitol 90 mL, prn) furosemide iv

##### PES membrane filter 사용:
- 병동에서 청구하여 사용가능 
- 청구번호 8809228832019 (ECO IV FILTER LINE 0.22 MICRO) 또는 청구번호 0105034480104373(AEF1E)

##### D21 OPD F/U with CBC+WBC diff, Adm batt, Chest PA

* 인정비급여 (허가만족, 100/100): 절제 가능한(종양크기 4cm 이상 또는 양성 림프절) 비소세포폐암에서 백금 기반 화학요법과의 병용투여로 수술 전 보조요법(neoadjuvant)

>NEJM 2022;386:1973-1985
Neoadj Nivo plus chemotherapy vs chemotherapy alone (AP, TC, GP)
N=358, EFS 31.6m vs 20.8m (HR 0.63), pCR 24.0% vs 2.2% (OR 13.94), G3/4 TRAE 33.5% vs 36.9%

---

### Neoadjuvant Nivolumab plus Paclitaxel/Carboplatin for NSCLC (squamous or nonsquamous)  (허가만족 100/100)

BSA:         m2

Nivolumab [D-code]    360 mg (fixed) miv over 30 min (with filter)
NS 50 mL
D1

Paclitaxel [D-code]         mg (175 mg/m2) miv over 3 hours (with filter)
D5W 500 mL
D1

Carboplatin [D-code]       mg (AUC: 5) miv over 1 hour
D5W 500 mL  
(total dose가 264 mg 미만인 경우 D5W 200 mL mix; 106 mg 미만인 경우 D5W 100 mL mix)                             
D1    

q 3 weeks (for 3 cycles)
 
>▶ 투약순서: Nivolumab → Premed → Paclitaxel → CBDCA

##### Supportive cares
1. Antiemetics (고위험군) (보험) :
D1 Akynzeo (Netupitant + palonosetron) PO; dexa는 paclitaxel premed로 대체
+/- D2-4 Dexa 8 mg qd iv or po (추가 시 지정의 선생님 상의)
	Cf. 고위험군: Carboplatin AUC ≥4, 중등도위험군: Carboplatin AUC <4
2. To prevent paclitaxel hypersensitivity (30 min before paclitaxel)
Chlorpheniramine 1A + famotidine 1A/D5W 50 mL + dexa 10 mg ivs
3. 퇴원 시 NSAIDs 처방 for myalgia

##### PES membrane filter 사용:
- 병동에서 청구하여 사용가능 
- 청구번호 8809228832019 (ECO IV FILTER LINE 0.22 MICRO) 또는 청구번호 0105034480104373(AEF1E)

##### D21 OPD F/U with CBC+WBC diff, Adm batt, Chest PA

* 인정비급여 (허가만족, 100/100): 절제 가능한(종양크기 4cm 이상 또는 양성 림프절) 비소세포폐암에서 백금 기반 화학요법과의 병용투여로 수술 전 보조요법(neoadjuvant)

>NEJM 2022;386:1973-1985
Neoadj Nivo plus chemotherapy vs chemotherapy alone (AP, TC, GP)
N=358, EFS 31.6m vs 20.8m (HR 0.63), pCR 24.0% vs 2.2% (OR 13.94), G3/4 TRAE 33.5% vs 36.9%

---

### Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin for NSCLC (squamous) (허가만족 100/100)

BSA:    m2

Nivolumab [D-code]    360 mg (fixed)  miv over 30 min (with filter)
NS 50 mL
D1

Gemcitabine [D-code]        mg (1000 mg/m2) miv over 30 min 
NS 50 mL                                 
D1, 8

Cisplatin [D-code]         mg (75 mg/m2) miv over 30 min 
N/S 150 mL 
D1

q 3 weeks (for 3 cycles)

>▶ 투약순서: Nivolumab → Prehydration (2 hr) → dexa, Antiemetics (-30 min) → 15% mannitol (-15 min) → CDDP → Posthydration (2 hr) → Gemcitabine

#### Supportive care
1. Antiemetics (고위험군) (보험):
D1 Akynzeo (Netupitant + palonosetron) PO + Dexa 12 mg
+/- D2-4 Dexa 8 mg qd iv or po (추가 시 지정의 선생님 상의)
D8 metoclopramide (EPS 유의), prn) ativan
2. Hydration
- ONH with Oral hydration 1.5 L 
- CDDP: pre/post NK2 2L, 15% mannitol 90 mL, prn) furosemide iv

##### PES membrane filter 사용:
- 병동에서 청구하여 사용가능 
- 청구번호 8809228832019 (ECO IV FILTER LINE 0.22 MICRO) 또는 청구번호 0105034480104373(AEF1E)

##### D21 OPD F/U with CBC+WBC diff, Adm batt, Chest PA

* 인정비급여 (허가만족, 100/100): 절제 가능한(종양크기 4cm 이상 또는 양성 림프절) 비소세포폐암에서 백금 기반 화학요법과의 병용투여로 수술 전 보조요법(neoadjuvant)

>NEJM 2022;386:1973-1985
Neoadj Nivo plus chemotherapy vs chemotherapy alone (AP, TC, GP)
N=358, EFS 31.6m vs 20.8m (HR 0.63), pCR 24.0% vs 2.2% (OR 13.94), G3/4 TRAE 33.5% vs 36.9%

---

### Neoadjuvant Gemcitabine/CDDP for stage IIIA NSCLC (single N2, non-bulky N2)

BSA:         m2 

Gemcitabine        mg (1250 mg/m2) miv over 30 min 
NS 50 mL 
D1, 8

Cisplatin          mg (60 mg/m2) miv over 30 min 
N/S 150 mL 
D1

q 3 weeks

>▶ 투약순서: Prehydration (2 hr) → dexa, Antiemetics (-30 min) → 15% mannitol (-15 min) → CDDP 
→ Posthydration (2 hr) → Gemcitabine

#### Supportive cares
1. Antiemetics (고위험군): 
D1 Akynzeo (Netupitant + palonosetron) PO + Dexa 12 mg
D2-4 Dexa 8 mg qd iv or po 
D8 metoclopramide (EPS 유의), prn) ativan
2. Hydration
- ONH with Oral hydration 1.5 L 
- CDDP: pre/post NK2 2 L, 15% mannitol 90 mL, prn) furosemide iv

#### D21 OPD F/U with CBC+WBC diff, Adm batt, CPA

*선행화학요법(neoadjuvant)에 효과가 있는 요법의 경우 수술후보조요법(adjuvant)으로 연장투여 가능함. (선행화학요법과 수술후보조요법을 포함하여 4주기까지 인정)

---

### Adjuvant Atezolizumab for non-small cell lung cancer (PD-L1 SP263≥50%, stage II-IIIA by TNM 7th edition, following adjuvant chemotherapy) [허가만족 100/100]
 
Atezolizumab [D] 1200 mg miv over 60 min (with filter: 0.2 ~ 0.22 microgram)
(If tolerable, over 30 min)
NS 250 mL 
D1

q 3 weeks (for 16 cycles or 1 year)

####  PES membrane filter 사용: 
- 병동에서 청구하여 사용가능, 
- 청구번호 8809228832019(ECO IV FILTER LINE 0.22 MICRO) 또는 청구번호 0105034480104373 (AEF1E)

#### D21 OPD F/U with CBC+WBC diff, Adm batt, CPA

#### 2022-11 허가사항
><u>PD-L1 발현 비율이 종양세포(TC)의 50% 이상 (<mark>SP263 Ab</mark>) 인 병기 II-IIIA (TNM 7판 기준) 비소세포폐암 환자에 대해 절제 및 <mark>백금 기반 화학요법 후 (최대 4주기의 adjuvant chemo)</mark> 수술 후 보조요법(adjuvant) / 이 약은 질병 재발 또는 허용 불가능한 독성이 발생하지 않는 한 <mark>1년 동안</mark> 투여한다</u>

#### <u>Stage II-IIIA (AJCC 7th edition) 기준 (뒷장 표 참고, 표는 블루시트에 복사하지 말 것)</u>
 -	N0 라면 Tumor size 5cm 초과 (5cm은 포함되지 않음)
 -	N1, N2 전체 (T4N2는 제외)
 -	N3는 대상 아님

Size 기준 T staging: T1a (≤2cm), T1b (≤3cm), T2a(≤5cm), T2b (≤7cm), T3(>7cm), T4(size기준없음)
기타 기준 T staging은 뒷장 표 참조 (표는 블루시트에 복사하지 않을 것)
Cf> AJCC 7th Ed. stage IIIB: T4N1, TxN3

Lancet 2021;398(10308):1344-1357, Atezolizumab vs Best supportive care (N=507 vs 498)
DFS in stage II-IIIA with PD-L1 >=1%: HR 0.66, DFS in stage II-IIIA with all PD-L1: HR 0.79, G3-4 AE 11%

---

### TNM 7 vs 8 th Edition 비교/IMPOWER 010 대상

 ![Table001](./image001.png)
 
---

### Adjuvant Pembrolizumab for NSCLC (PD-L1 all comer) (허가만족 100/100)

BSA:    m2

Pembrolizumab [D-code]   200 mg (fixed) miv over 30 min (with filter)
NS 50 mL bag (final conc. 1~10 mg/mL 되도록 조정)
D1

q 3 weeks (for 18 cycles or 1 year)

#### 0.2-0.5 micron filter/or add-on filter 사용해서 주입 

#### D22 OPD F/U with CBC+WBC diff, Adm batt, CPA

#### 허가사항
절제술과 백금 기반 화학요법제 치료를 받은 IB기(T2a ≥4cm), II기 또는 IIIA기 비소세포폐암 환자에서의 수술 후 보조요법(adjuvant)으로서 단독요법

>Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12. PMID: 36108662.
mDFS 53.6mo vs. 42.0mo, HR 0.76 (0.63-0.91) in the overall population

---
